$5.83
-0.03 (-0.54%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CNSP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeNCT04762069Overall SurvivalRandomized · Single-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Berubicin, Lomustine | Glioblastoma Multiforme, Adult | 252 | 2026-04-27 | 2026-04-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19